ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Antiviral drugs >Lopinavir

Lopinavir

Lopinavir Suppliers list
Company Name: Alpha Biopharmaceuticals Co., Ltd
Tel: 0086-411-39042497
Email: sales@alphabiopharm.com
Products Intro: Product Name:Lopinavir
CAS:192725-17-0
Purity:98% Package:1g,5g,25g,100g Remarks:B0226
Company Name: Capot Chemical Co.,Ltd.
Tel: +86 (0)571-855 867 18
Email: sales@capotchem.com
Products Intro: Product Name:Lopinavir
CAS:192725-17-0
Purity:98%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Email: info@dakenchem.com
Products Intro: Product Name:Lopinavir
CAS:192725-17-0
Purity:99% Package:100g,500g,1KG,10KG,100KG
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd.
Tel: +86-10-60279497 +86(0)15646567669
Email: sales01@cooperate-pharm.com
Products Intro: Product Name:lopinavir
CAS:192725-17-0
Purity:98% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: Hebei Jiangkai Trading Co., Ltd
Tel: 0086-17197824289/17197824028
Email: alice@hbjkai.com
Products Intro: Product Name:lopinavir;ABT-378 whatsapp;+8617197824028
CAS:192725-17-0
Purity:98 Wahtsapp;+8617197824028 Package:500G;100USD

Lastest Price from Lopinavir manufacturers

  • Lopinavir
  • US $1.00 / KG
  • 2019-04-01
  • CAS:192725-17-0
  • Min. Order: 1G
  • Purity: 98%
  • Supply Ability: 100KG
Lopinavir Basic information
Product Name:Lopinavir
Synonyms:(aS)-N-[(1S,3S,4S)-4-[[2-(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-α-(1-methylethyl)-2-oxo-1(2H)-Pyrimidineacetamide;Koletra;(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenyl-hexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide;Lopinavir (ABT-378);Lopinavir (350 mg);(αS)-N-[(1S,3S,4S)-4-[[2-(2,6-DiMethylphenoxy)acetyl]aMino]-3-hydroxy-5-phenyl-1-(phenylMethyl)pentyl]tetrahydro-α-(1-Methylethyl)-2-oxo-1(2H)-pyriMidineacetaMide;(2S)-N-[(2S,4S,5S)-5-[2-(2,6-diMethylphenoxy)acetaMido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-Methyl-2-(2-oxo-1,3-diazinan-1-yl)butanaMide;(S)-N-((2R,4S,5S)-5-(2-(2,6-Dimethylphenoxy)acetamido)-4-hydroxy-1,6-diphenyl-hexn-2-yl)-3-methyl
CAS:192725-17-0
MF:C37H48N4O5
MW:628.8
EINECS:
Product Categories:-;Anti-viral Compounds;Anti-virals;Intermediates & Fine Chemicals;Non-nucleoside Reverse Transcriptase;Pharmaceuticals;Chiral Reagents;Pepetides;ProteaseInhibitors;API;peptides;ABT-378;Other APIs
Mol File:192725-17-0.mol
Lopinavir Structure
Lopinavir Chemical Properties
Melting point 124-127°C
storage temp. Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility DMSO: soluble20mg/mL, clear
form powder
color white to beige
optical activity[α]/D -20 to -27°, c = 0.4 in methanol
Stability:Hygroscopic
CAS DataBase Reference192725-17-0(CAS DataBase Reference)
Safety Information
RIDADR 3077
HS Code 29335990
MSDS Information
Lopinavir Usage And Synthesis
Chemical PropertiesWhite Crystalline Solid
UsesA selective HIV protease inhibitor. An analogue of Ritonavir. Antiviral.
UsesLopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM
DefinitionChEBI: A dicarboxylic acid amide in which a parent structure of amphetamine is substituted on nitrogen by a (2,6-dimethylphenoxy)acetyl group and on the carbon alpha to nitrogen by a (1S,3S)-1-hydroxy-3-{[(2S)-3- ethyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanoyl]amino}-4-phenylbutyl group. An antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.
Antimicrobial activityLopinavir is active against HIV-1 and HIV-2.
Acquired resistanceSignificant resistance to the antiretroviral efficacy of ritonavirbooted lopinavir occurs as a result of amino acid substitutions at positions 32, 47 and 82 in the protease region. Protease inhibitor resistance is uncommon in patients identified with early failure of combination therapy with ritonavir boostedlopinavir and nucleotide reverse transcriptase inhibitors.
General DescriptionLopinavir is a protease inhibitor that has been approved foruse in combination with ritonavir for patients with HIV whohave not responded to other treatment modalities. Lopinaviris used in excess over ritonavir. Ritonavir at amounts givenhas no antiretroviral activity, Ritonavir inhibits lopinavir’smetabolism by CYP3A4, causing a higher level of lopinavirin the system. The combination is the first protease inhibitorapproved for patients as young as 6 months of age.
Pharmaceutical ApplicationsA synthetic compound, co-formulated with ritonavir for oral administration. In this formulation, ritonavir functions to inhibit the metabolic clearance of lopinavir, and does not contribute to the antiretroviral activity.
PharmacokineticsOral absorption: Not known/available
Cmax 400 mg + ritonavir 100 mg twice daily: c. 9.6 mg/L
Cmin 400 mg + ritonavir 100 mg twice daily: c. 5.5 mg/L
Plasma half-life: c. 5–6 h
Volume of distribution: Not known/available
Plasma protein binding: c. 98–99%
Absorption and distribution
The absorption of lopinavir–ritonavir in capsule or liquid form is favorably affected by the presence of food, particularly if high in fat. The CNS penetration is good. It has a semen:plasma ratio of 0.07. It is distributed into breast milk.
Metabolism
Lopinavir is extensively metabolized by the CYP3A4 system, but this is inhibited by ritonavir.
Excretion
Over an 8-day period after single dosing with the combined formulation, around 10% and 83% of the administered dose is recovered in urine and feces, respectively. Less than 3% of the dose is recovered as unchanged drug in urine and 20% in feces. In mild to moderate hepatic impairment, an increase in exposure of approximately 30% is observed, but is probably not clinically relevant. It should be avoided in severe hepatic impairment.
Clinical UseTreatment of HIV infection (in combination with ritonavir and other antiretroviral agents)
Side effectsThe most common adverse events seen in trials of complex antiretroviral regimens were diarrhea, nausea, headache, fatigue, vomiting and rash. Ritonavir-boosted lopinavir is associated with a dyslipidemia profile characteristic of those treated with other protease inhibitors boosted with 200 mg of ritonavir.
Lopinavir Preparation Products And Raw materials
Tag:Lopinavir(192725-17-0) Related Product Information
LOPINAVIR, [3H]- LOPINAVIR-D8 Lopinavir Diphenyldiethoxysilane Diphenyldimethoxysilane AMINO ACIDS Sodium triacetoxyborohydride Glycine 6-Aminocaproic acid Acetyl-resveratrol Diphenylsilanediol Acetylacetone Acetoxyacetyl chloride CHLOROPHOSPHONAZO III ALTRENOGEST Acetoxyacetic acid Tris Base Dimethyldimethoxysilane